Study identifier:SD-039-0668
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler as Single Therapy in subjects with moderate-severe asthma. Comparison with conventional asthma therapy, Pulmicort(budesonide) Turbuhaler as regular treatment complemented with Bricanyl(terbutaline) Turbuhaler.
asthma
Phase 3
-
-
-
-
Interventional
-
Allocation: - 
Endpoint Classification: - 
Intervention Model: - 
Masking: - 
Primary Purpose: - 
Verified 01 May 2025 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|